

Arthur M Krieg

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11141205/arthur-m-krieg-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192
papers

23,980
citations

74
h-index

153
g-index

201
ext. papers

25,253
ext. citations

8.1
avg. IF

7.13
L-index

#	Paper	IF	Citations
192	CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> , 1995 , 374, 546-9	50.4	3023
191	CpG motifs in bacterial DNA and their immune effects. <i>Annual Review of Immunology</i> , 2002 , 20, 709-60	34.7	2122
190	Therapeutic potential of Toll-like receptor 9 activation. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 471-84	64.1	969
189	CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. <i>Journal of Experimental Medicine</i> , 1997 , 186, 1623-31	16.6	883
188	Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. <i>European Journal of Immunology</i> , 2001 , 31, 2154-63	6.1	733
187	Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. <i>Nature Immunology</i> , 2002 , 3, 499	19.1	723
186	Mechanism and function of a newly identified CpG DNA motif in human primary B cells. <i>Journal of Immunology</i> , 2000 , 164, 944-53	5.3	530
185	Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. <i>Journal of Immunology</i> , 2000 , 164, 1617-24	5.3	512
184	Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. <i>Journal of Immunology</i> , 2004 , 173, 4433-42	5.3	511
183	Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. <i>Journal of Clinical Investigation</i> , 2005 , 115, 739-46	15.9	497
182	Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. <i>European Journal of Immunology</i> , 2004 , 34, 251-62	6.1	480
181	Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. <i>Advanced Drug Delivery Reviews</i> , 2009 , 61, 195-204	18.5	446
180	Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. <i>Journal of Experimental Medicine</i> , 2005 , 202, 1575-85	16.6	436
179	Development of TLR9 agonists for cancer therapy. <i>Journal of Clinical Investigation</i> , 2007 , 117, 1184-94	15.9	320
178	The role of CpG motifs in innate immunity. <i>Current Opinion in Immunology</i> , 2000 , 12, 35-43	7.8	295
177	Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. <i>Immunological Reviews</i> , 2007 , 220, 251-69	11.3	270
176	CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. <i>Vaccine</i> , 1998 , 16, 1216-24	4.1	247

175	CpG motifs: the active ingredient in bacterial extracts?. <i>Nature Medicine</i> , 2003 , 9, 831-5	50.5	246
174	Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. <i>Clinical Immunology and Immunopathology</i> , 1997 , 84, 185-93		242
173	Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. <i>Journal of Immunology</i> , 2008 , 180, 3729-38	5.3	225
172	The role of CpG dinucleotides in DNA vaccines. <i>Trends in Microbiology</i> , 1998 , 6, 23-7	12.4	214
171	Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. <i>Journal of Immunology</i> , 2004 , 172, 4926-33	5.3	213
170	Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. <i>Antisense Research and Development</i> , 1993 , 3, 53-66		206
169	Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. <i>Journal of Immunology</i> , 2001 , 167, 4878-86	5.3	205
168	Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5716-24	2.2	186
167	Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. <i>Current Oncology Reports</i> , 2004 , 6, 88-95	6.3	182
166	CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. <i>Oligonucleotides</i> , 2001 , 11, 333-40		180
165	Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. <i>Journal of Immunology</i> , 2002 , 168, 4711-20	5.3	179
164	Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma. <i>Blood</i> , 1997 , 89, 2994-2998	2.2	171
163	Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. <i>Journal of Immunotherapy</i> , 2004 , 27, 460-71	5	168
162	CpG still rocks! Update on an accidental drug. <i>Nucleic Acid Therapeutics</i> , 2012 , 22, 77-89	4.8	153
161	CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. <i>Aids</i> , 2005 , 19, 1473-9	3.5	152
160	New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. <i>Journal of Immunology</i> , 2006 , 177, 1670-8	5.3	149
159	Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. <i>Journal of Immunology</i> , 2000 , 165, 6278-86	5.3	148
158	CpG DNA: a pathogenic factor in systemic lupus erythematosus?. <i>Journal of Clinical Immunology</i> , 1995 , 15, 284-92	5.7	145

157	CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. <i>Vaccine</i> , 2000 , 18, 1920-44.1		143
156	Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3979-86	2.2	142
155	Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. <i>Infection and Immunity</i> , 2001 , 69, 1643-9	3.7	135
154	Endogenous retroviruses: potential etiologic agents in autoimmunity. <i>FASEB Journal</i> , 1992 , 6, 2537-44	0.9	130
153	CpG oligodeoxynucleotide enhances tumor response to radiation. <i>Cancer Research</i> , 2004 , 64, 5074-7	10.1	127
152	Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. <i>European Journal of Immunology</i> , 2002 , 32, 1212-22	6.1	127
151	Immune effects and mechanisms of action of CpG motifs. <i>Vaccine</i> , 2000 , 19, 618-22	4.1	127
150	Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. <i>Journal of Immunotherapy</i> , 2006 , 29, 558-68	5	124
149	Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. <i>Vaccine</i> , 1999 , 17, 3065-71	4.1	124
148	CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1999 , 104, 1258-64 ^{11.5}		124
147	Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. <i>Immunology</i> , 2004 , 113, 212-23	7.8	119
146	Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. <i>Trends in Microbiology</i> , 1996 , 4, 73-6	12.4	116
145	Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1998 , 92, 3730-3736	2.2	113
144	Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1999 , 1489, 107-16		113
143	The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. <i>Journal of Virology</i> , 2005 , 79, 14355-70	6.6	112
142	Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. <i>Trends in Immunology</i> , 2000 , 21, 521-6		110
141	CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. <i>Journal of Immunology</i> , 2000 , 165, 6889-95	5.3	110
140	Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. <i>Journal of Immunology</i> , 2007 , 179, 2493-500	5.3	106

139	Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. <i>Clinical Cancer Research</i> , 2005 , 11, 361-9	12.9	105
138	Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non HodgkinB lymphoma. <i>Clinical Cancer Research</i> , 2007 , 13, 6168-74	12.9	102
137	An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. <i>Translational Research</i> , 1996 , 128, 128-33		101
136	CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. <i>Clinical Cancer Research</i> , 2003 , 9, 3105-14	12.9	100
135	Retroviruses and autoimmunity. <i>Journal of Autoimmunity</i> , 1990 , 3, 137-66	15.5	97
134	Direct immunologic activities of CpG DNA and implications for gene therapy. <i>Journal of Gene Medicine</i> , 1999 , 1, 56-63	3.5	97
133	CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. <i>Journal of Immunology</i> , 2004 , 173, 5148-55	5.3	91
132	CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. <i>Oligonucleotides</i> , 2001 , 11, 247-56		89
131	CpG DNA is an effective oral adjuvant to protein antigens in mice. <i>Vaccine</i> , 2000 , 19, 950-7	4.1	88
130	Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. <i>Antisense Research and Development</i> , 1991 , 1, 161-71		87
129	TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. <i>Journal of Immunology</i> , 2007 , 179, 3937-46	5.3	86
128	CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. <i>Infection and Immunity</i> , 2004 , 72, 949-57	3.7	84
127	Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E797-803	11.5	82
126	CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. <i>Cancer Research</i> , 2003 , 63, 394-9	10.1	81
125	CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. <i>International Immunology</i> , 1999 , 11, 2015-24	4.9	79
124	Antiinfective applications of toll-like receptor 9 agonists. <i>Proceedings of the American Thoracic Society</i> , 2007 , 4, 289-94		78
123	Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 615-28	7.4	77
122	Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. <i>European Journal of Immunology</i> , 2006 , 36, 1815-26	6.1	77

121	Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Oligonucleotides</i> , 1996 , 6, 133-9		75
120	Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. <i>Journal of Infectious Diseases</i> , 2012 , 205, 1294-304	7	74
119	Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. <i>Journal of Immunology</i> , 2001 , 167, 2921-8	5:3	72
118	APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. <i>Journal of Immunology</i> , 2000 , 165, 6244-51	5:3	72
117	Theoretical and experimental approaches to generalized autoimmunity. <i>Immunological Reviews</i> , 1990 , 118, 129-63	11:3	72
116	Now I know my CpGs. <i>Trends in Microbiology</i> , 2001 , 9, 249-52	12:4	71
115	Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. <i>International Archives of Allergy and Immunology</i> , 1999 , 118, 457-61	3:7	71
114	Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. <i>Blood</i> , 2001 , 98, 1217-25	2:2	70
113	Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. <i>Cellular Immunology</i> , 2007 , 250, 75-84	4:4	68
112	Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB. <i>International Immunology</i> , 2001 , 13, 1391-404	4:9	68
111	TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. <i>Blood</i> , 2008 , 112, 3508-16	2:2	67
110	CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. <i>Journal of Immunology</i> , 2003 , 170, 4061-8	5:3	67
109	Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. <i>Blood</i> , 2002 , 100, 4169-76	2:2	67
108	Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. <i>Journal of Immunology</i> , 2006 , 177, 1028-39	5:3	66
107	Toll-like receptor 9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by Legionella pneumophila. <i>Infection and Immunity</i> , 2008 , 76, 2895-904	3:7	64
106	A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. <i>Oligonucleotides</i> , 2010 , 20, 93-101		58
105	C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. <i>Immunobiology</i> , 2004 , 209, 141-54	3:4	58
104	Mechanisms and therapeutic applications of immune stimulatory cpG DNA 1999 , 84, 113-20		58

103	Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. <i>Oligonucleotides</i> , 1998 , 8, 351-6		57
102	High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. <i>Journal of Immunology</i> , 2006 , 177, 8701-7	5.3	55
101	Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with <i>Burkholderia pseudomallei</i> . <i>Infection and Immunity</i> , 2004 , 72, 4494-502	3.7	55
100	A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. <i>Vaccine</i> , 2008 , 26, 4849-59	4.1	54
99	Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. <i>International Immunology</i> , 2003 , 15, 577-91	4.9	50
98	Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. <i>Oligonucleotides</i> , 2002 , 12, 165-75		50
97	Stimulation via Toll-like receptor 9 reduces <i>Cryptococcus neoformans</i> -induced pulmonary inflammation in an IL-12-dependent manner. <i>European Journal of Immunology</i> , 2005 , 35, 273-81	6.1	48
96	From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. <i>Oligonucleotides</i> , 2001 , 11, 181-8		47
95	Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. <i>Immunology</i> , 2007 , 120, 526-35	7.8	46
94	CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. <i>Journal of Endotoxin Research</i> , 2004 , 10, 431-8		46
93	Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. <i>Vaccine Journal</i> , 2005 , 12, 606-21		46
92	Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. <i>Immunological Reviews</i> , 1999 , 168, 217-39	11.3	46
91	Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). <i>Oligonucleotides</i> , 2004 , 14, 23-31		44
90	CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. <i>Antiviral Research</i> , 2005 , 65, 87-95	10.8	44
89	Oligonucleotides with novel, cationic backbone substituents: aminoethylphosphonates. <i>Nucleic Acids Research</i> , 1994 , 22, 5416-24	20.1	44
88	Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. <i>Journal of Interferon and Cytokine Research</i> , 1997 , 17, 781-8	3.5	43
87	Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. <i>International Journal of Cancer</i> , 2007 , 121, 1520-8	7.5	40
86	Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. <i>International Immunology</i> , 2003 , 15, 223-31	4.9	40

85	Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. <i>American Journal of Obstetrics and Gynecology</i> , 2001 , 185, 1174-9	6.4	39
84	Heterogeneous expression and coordinate regulation of endogenous retroviral sequences in human peripheral blood mononuclear cells. <i>AIDS Research and Human Retroviruses</i> , 1992 , 8, 1991-8	1.6	39
83	P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. <i>Oligonucleotides</i> , 2003 , 13, 491-9		38
82	CpG DNA: trigger of sepsis, mediator of protection, or both?. <i>Scandinavian Journal of Infectious Diseases</i> , 2003 , 35, 653-9		38
81	Antibody repertoire development in fetal and neonatal piglets. IX. Three pathogen-associated molecular patterns act synergistically to allow germfree piglets to respond to type 2 thymus-independent and thymus-dependent antigens. <i>Journal of Immunology</i> , 2005 , 175, 6772-85	5.3	37
80	CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. <i>International Immunology</i> , 2001 , 13, 1013-20	4.9	36
79	CpG DNA: a novel immunomodulator. <i>Trends in Microbiology</i> , 1999 , 7, 64-5	12.4	35
78	A CpG oligonucleotide can protect mice from a low aerosol challenge dose of <i>Burkholderia mallei</i> . <i>Infection and Immunity</i> , 2006 , 74, 1944-8	3.7	34
77	Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. <i>International Immunology</i> , 2009 , 21, 607-19	4.9	33
76	Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. <i>Clinical Immunology and Immunopathology</i> , 1993 , 67, 130-6		33
75	Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. <i>Journal of Immunological Methods</i> , 2001 , 247, 83-94	2.5	32
74	Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. <i>Journal of Endotoxin Research</i> , 2004 , 10, 247-51		31
73	Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. <i>Antisense Research and Development</i> , 1992 , 2, 325-30		31
72	Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON [®]) an Investigational Synthetic Toll-like Receptor 9 Agonist. <i>Antiviral Therapy</i> , 2007 , 12, 741-751	1.6	31
71	Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists. <i>ChemMedChem</i> , 2006 , 1, 1007-14	3.7	29
70	Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotypic vaccine that mimics carcinoembryonic antigen. <i>Cancer Immunology, Immunotherapy</i> , 2003 , 52, 317-27	7.4	29
69	Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. <i>Biochemical Pharmacology</i> , 2005 , 69, 981-91	6	29
68	The toll of too much TLR7. <i>Immunity</i> , 2007 , 27, 695-7	32.3	28

67	Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. <i>Veterinary Immunology and Immunopathology</i> , 2007 , 115, 24-34	2	26
66	CpG oligodeoxynucleotides augment the murine immune response to the <i>Yersinia pestis</i> F1-V vaccine in bubonic and pneumonic models of plague. <i>Vaccine</i> , 2009 , 27, 2220-9	4.1	25
65	CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 515-27	7.4	25
64	Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding. <i>Oligonucleotides</i> , 2006 , 16, 58-67		25
63	Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. <i>Vaccine</i> , 2006 , 24, 6155-62	4.1	25
62	Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 2314-7	5.9	25
61	Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. <i>Experimental Hematology</i> , 2006 , 34, 1403-12	3.1	23
60	Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2006 , 41, 1361-8	2.6	23
59	Immune effects and therapeutic applications of CpG motifs in bacterial DNA. <i>Immunopharmacology</i> , 2000 , 48, 303-5		23
58	Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. <i>Oligonucleotides</i> , 2003 , 13, 143-50		22
57	Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. <i>Journal of Infectious Diseases</i> , 2011 , 204, 636-44	7	21
56	Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent <i>Listeria monocytogenes</i> . <i>Infection and Immunity</i> , 2003 , 71, 4398-404	3.7	21
55	Increased expression of novel full-length endogenous mink cell focus-forming-related transcripts in autoimmune mouse strains. <i>Virology</i> , 1988 , 162, 274-6	3.6	21
54	Type I interferon is the primary regulator of inducible Ly-6C expression on T cells. <i>Journal of Interferon and Cytokine Research</i> , 2001 , 21, 621-9	3.5	20
53	Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization. <i>Journal of Immunology</i> , 2020 , 204, 1386-1394	5.3	20
52	Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif. <i>Nucleic Acid Therapeutics</i> , 2011 , 21, 201-14	4.8	19
51	Expression of an endogenous retroviral transcript is associated with murine lupus. <i>Arthritis and Rheumatism</i> , 1989 , 32, 322-9		19
50	NK cells activated in vivo by bacterial DNA control the intracellular growth of <i>Francisella tularensis</i> LVS. <i>Microbes and Infection</i> , 2009 , 11, 49-56	9.3	18

49	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. <i>Cancer Discovery</i> , 2021 ,	24.4	17
48	Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. <i>Antiviral Therapy</i> , 2007 , 12, 741-51	1.6	17
47	Activation of innate immunity in healthy <i>Macaca mulatta</i> macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques. <i>Vaccine Journal</i> , 2008 , 15, 221-6		16
46	Inhibition of T4 polynucleotide kinase activity by phosphorothioate and chimeric oligodeoxynucleotides. <i>Antisense Research and Development</i> , 1994 , 4, 295-7		16
45	Retroviruses and Their Roles in Chronic Inflammatory Diseases and Autoimmunity 1995 , 491-603		16
44	Attenuated cytokine responses in porcine lymph node cells stimulated with CpG DNA are associated with low frequency of IFN α -producing cells and TLR9 mRNA expression. <i>Veterinary Immunology and Immunopathology</i> , 2008 , 123, 324-36	2	15
43	Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers. <i>Journal of Immune Based Therapies and Vaccines</i> , 2008 , 6, 3		15
42	Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. <i>Journal of Leukocyte Biology</i> , 2004 , 76, 585-93	6.5	14
41	Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. <i>Oligonucleotides</i> , 2002 , 12, 155-64		14
40	A possible cause of joint destruction in septic arthritis. <i>Arthritis Research</i> , 1999 , 1, 3-4		14
39	Rescue of B cells from apoptosis by immune stimulatory CpG DNA. <i>Seminars in Immunopathology</i> , 2000 , 22, 55-61		13
38	Minding the Cs and Gs. <i>Molecular Therapy</i> , 2000 , 1, 209-10	11.7	13
37	The CpG motif: implications for clinical immunology. <i>BioDrugs</i> , 1998 , 10, 341-6	7.9	13
36	Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. <i>Oligonucleotides</i> , 1997 , 7, 115-23		12
35	Accumulation of glutathione disulfide mediates NF-kappaB activation during immune stimulation with CpG DNA. <i>Oligonucleotides</i> , 2002 , 12, 327-40		12
34	Bacterial DNA does not increase serum corticosterone concentration or prevent increases induced by other stimuli. <i>International Immunopharmacology</i> , 2001 , 1, 1605-14	5.8	12
33	CD14+ cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands. <i>Veterinary Immunology and Immunopathology</i> , 2008 , 126, 273-82	2	11
32	Immunology. The toll of cathepsin K deficiency. <i>Science</i> , 2008 , 319, 576-7	33.3	11

31	Interruption of a transforming growth factor alpha autocrine loop in Caco-2 cells by antisense oligodeoxynucleotides. <i>Gastroenterology</i> , 1995 , 109, 1882-9	13.3	11
30	Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment. <i>Immunobiology</i> , 2011 , 216, 12-23	3.4	10
29	Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep. <i>Veterinary Immunology and Immunopathology</i> , 2007 , 115, 357-68	2	10
28	Applications of antisense oligodeoxynucleotides in immunology and autoimmunity research. <i>ImmunoMethods</i> , 1992 , 1, 191-202		10
27	Direct Immunologic activities of CpG DNA and implications for gene therapy. <i>Journal of Gene Medicine</i> , 1999 , 1, 56-63	3.5	9
26	AIMing 2 detect foreign DNA. <i>Science Signaling</i> , 2009 , 2, pe39	8.8	8
25	Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides. <i>Vaccine</i> , 2004 , 22, 2641-50	4.1	8
24	Signal transduction induced by immunostimulatory CpG DNA. <i>Seminars in Immunopathology</i> , 2000 , 22, 97-105		8
23	Subcutaneous, but not intratracheal administration of the TLR9 agonist, CpG DNA transiently reduces parainfluenza-3 virus shedding in newborn lambs. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2010 , 33, e111-7	2.6	7
22	Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. <i>Expert Opinion on Drug Discovery</i> , 2009 , 4, 587-603	6.2	6
21	PD3-1-6: PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007 , 2, S461	8.9	6
20	B cells express Ly-6C in a Th1 but not Th2 cytokine environment. <i>Journal of Interferon and Cytokine Research</i> , 2002 , 22, 799-806	3.5	6
19	Molecular aspects of systemic lupus erythematosus: murine endogenous retroviral expression. <i>DNA and Cell Biology</i> , 1992 , 11, 253-7	3.6	6
18	CpG Oligodeoxynucleotides 2001 , 31, 229-232		5
17	Role of endogenous retroviruses in autoimmune diseases. <i>Tohoku Journal of Experimental Medicine</i> , 1994 , 173, 105-14	2.4	4
16	CpG ODN As a Th1 Immune Enhancer for Prophylactic and Therapeutic Vaccines 2006 , 87-110		4
15	The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays. <i>Microbial Pathogenesis</i> , 2013 , 63, 16-8	3.8	3
14	Potential use of CpG ODN for cancer immunotherapy. <i>Update on Cancer Therapeutics</i> , 2006 , 1, 49-58		3

- 13 Potential of Antisense Technology in the Treatment of Immunological Disorders. *BioDrugs*, **1995**, 4, 169-179 3
- 12 Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. *Progress in Respiratory Research*, **2010**, 95-99 2
- 11 Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor. *Blood*, **1998**, 92, 3730-3736 2.2 2
- 10 Identification of CpG oligonucleotide sequences with high induction of IFN- γ in plasmacytoid dendritic cells **2001**, 31, 2154 2
- 9 Applications of CpG Motifs from Bacterial DNA in Cancer Immunotherapy **2002**, 268-286 1
- 8 Immune Effects of Bacterial DNA and Their Possible Role in the Pathogenesis of Lupus **1999**, 79-100 1
- 7 How to Exclude Immunostimulatory and Other Nonantisense Effects of Antisense Oligonucleotides. *Perspectives in Antisense Science*, **1999**, 79-89 1
- 6 Rigging Innate Immunity against the Flu. *Molecular Therapy*, **2017**, 25, 1993-1994 11.7
- 5 Stimulation of Toll-Like Receptor 9 for Enhancing Vaccination **2007**, 43-66
- 4 Signal transduction induced by immunostimulatory CpG DNA **2001**, 97-105
- 3 Rescue of B cells from apoptosis by immune stimulatory CpG DNA **2001**, 55-61
- 2 CpG Oligodeoxynucleotides for Mucosal Vaccines **2005**, 959-965
- 1 Immunostimulatory Potential of Silencing RNAs Can Be Mediated by a Non-Uridine-Rich Toll-Like Receptor 7 Motif. *Oligonucleotides*, 121102072334007